Trial Profile
Safety And Efficacy Of Weekly Administration Of S-8184 Paclitaxel Injectable Emulsion In Second Line Treatment Of Patients With Locally Advanced, Metastatic, Or Recurrent Transitional Cell Carcinoma Of The Urothelium.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Aug 2017
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary)
- Indications Bladder cancer; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sonus Pharmaceuticals
- 14 Nov 2008 OncoGenex Pharmaceuticals reported as a trial sponsor by ClinicalTrials.gov.
- 14 Nov 2008 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 06 Sep 2005 New trial record.